N/A N=15 Adolescent Attention to Emotion Study
Depression
Primary: Affect-biased Attention Following Neurofeedback (Immediately Post-Intervention) — .41 Proportion (0-1) — p=.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=434 Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With…
N/A N=692 The PEERLESS Study
Pulmonary Embolism · Pulmonary Thromboembolism
Primary: Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio — 52693; 10509 Number of Wins for the group
Phase 3 N=739 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Metastatic Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1% — 19.4; 23.5 Months — p=0.8335
Phase 1 N=36 A TQT Study of Effect of M2951 on Cardiac Repolarization
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
Phase 2 N=98 Fatty Acid Supplementation in Children With ASD (Study 2)
Autism Spectrum Disorder
Primary: Pervasive Developmental Disorder Behavior Inventory (PDDBI) - Autism Composite — 115.5; 106.5; 98.1; 91.4 raw score on a scale
N/A N=34 Pain Inflammation and Cannabis in HIV
HIV Infections · Neuropathic Pain · Cannabis
Primary: Change in Pain Severity Score — 6.44; 6.86; 8; 7.37 score on a scale — p=0.0303
Phase 1 N=24 Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Pleural Malignant Mesothelioma
Primary: Safety/Toxicity — 0; 0 participants
N/A N=208 Home-based tDCS and Mindfulness-based Meditation for Self-management of Clinical Pain and Symptoms
Osteo Arthritis Knee
Primary: Change in Numeric Rating Score (NRS) of Pain — -19.41; -7.16; -16.78; -6.20 units on a scale
Phase 1 N=45 A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Corona Virus Infection
Primary: Number of Patients With Any TEAEs During the Treatment Period Baseline to Day 14 — 5; 10 Participants
Phase 2 N=71 Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Non-vellus Target Area Hair Count (TAHC) — 20.3; 22.4; 14.0 hair count
Phase 1 N=87 A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
Breast Cancer
Primary: Percent Change From Baseline in Estrogen Receptor (ER) Expression — -88.89; -81.50; -70.13 percent change
Phase 1 N=26 Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Pediatric
Primary: Pharmacokinetics: Cmax — 19.12; 23.22 ng/mL
Phase 3 N=595 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
Triple Negative Breast Neoplasms
Primary: Overall Survival (OS) in PD-L1-positive Population — 11.24; 12.09 months — p=0.5891
N/A N=677 Fluorescent Cholangiography vs White Light for Bile Ducts Identification
Cholecystitis · Cholelithiasis
Primary: Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light — 64; 157; 159; 243 Participants